Jamie Dananberg Sells 5,290 Shares of Annexon (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) insider Jamie Dananberg sold 5,290 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total transaction of $26,979.00. Following the completion of the transaction, the insider owned 73,152 shares in the company, valued at $373,075.20. This represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Annexon Stock Performance

Shares of ANNX stock opened at $4.90 on Friday. The firm’s 50 day moving average price is $5.58 and its two-hundred day moving average price is $3.95. Annexon, Inc. has a 52-week low of $1.28 and a 52-week high of $7.18. The stock has a market cap of $586.19 million, a PE ratio of -3.48 and a beta of 1.17.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a report on Wednesday, January 21st. Chardan Capital began coverage on shares of Annexon in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $16.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Wednesday, January 14th. Finally, Wells Fargo & Company upped their target price on shares of Annexon from $14.00 to $27.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Annexon has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Institutional Trading of Annexon

A number of large investors have recently bought and sold shares of ANNX. Wealth Enhancement Advisory Services LLC raised its holdings in Annexon by 13.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 19,553 shares of the company’s stock worth $100,000 after buying an additional 2,348 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Annexon by 65.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after buying an additional 2,785 shares during the period. Susquehanna Portfolio Strategies LLC increased its position in shares of Annexon by 0.8% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 356,619 shares of the company’s stock worth $1,790,000 after acquiring an additional 2,875 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Annexon by 21.7% during the fourth quarter. ProShare Advisors LLC now owns 24,698 shares of the company’s stock worth $124,000 after acquiring an additional 4,410 shares in the last quarter. Finally, Citizens Financial Group Inc. RI raised its holdings in shares of Annexon by 14.3% during the third quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock worth $122,000 after acquiring an additional 5,000 shares during the period.

Trending Headlines about Annexon

Here are the key news stories impacting Annexon this week:

• Neutral Sentiment: Short-interest reports for Feb. 19–20 show 0 shares of reported short interest and a 0.0 days-to-cover metric — this appears to be a data/reporting anomaly (NaN changes). The readings do not indicate meaningful new short activity to explain the move. Short Interest Report
• Negative Sentiment: EVP Michael Overdorf sold 6,225 shares at an average $5.10 (≈$31.7k); his holdings fell ~4.8%. Form 4 – Overdorf
• Negative Sentiment: EVP Ted Yednock sold 7,857 shares at an average $5.11 (≈$40.1k); his position dropped ~7.5%. Form 4 – Yednock
• Negative Sentiment: EVP Dean Richard Artis sold 5,290 shares at an average $5.10 (≈$27.0k); his holding decreased ~4.1%. Form 4 – Artis
• Negative Sentiment: CFO Jennifer Lew sold 7,851 shares at an average $5.11 (≈$40.1k); her stake fell ~6.5%. Form 4 – Lew
• Negative Sentiment: Insider Jamie Dananberg sold 5,290 shares at an average $5.10 (≈$27.0k); his holding declined ~6.7%. Form 4 – Dananberg

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.